Case ReportCase Reports
Open Access

Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib

SHINYA TAKADA, KENGO UMEHARA and KENICHI WATANABE
In Vivo January 2026, 40 (1) 532-537; DOI: https://doi.org/10.21873/invivo.14217

Article Information

vol. 40 no. 1 532-537
DOI 
https://doi.org/10.21873/invivo.14217
PMID 
41482396
Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received September 18, 2025
  • Revision received October 23, 2025
  • Accepted November 5, 2025
  • Published online January 2, 2026.
Copyright & License 
Copyright © 2026 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

  1. SHINYA TAKADA1⇑,
  2. KENGO UMEHARA1 and
  3. KENICHI WATANABE2
  1. 1Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan;
  2. 2Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
  1. Shinya Takada, Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, 3-4 Kikusui, Shiroishi-ku, Sapporo, Hokkaido 0030804, Japan. Tel: +81018119111, e-mail: snowman198019{at}gmail.com
View Full Text

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib
SHINYA TAKADA, KENGO UMEHARA, KENICHI WATANABE
In Vivo Jan 2026, 40 (1) 532-537; DOI: 10.21873/invivo.14217
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords